

Affiliation	Investigator Clinical Neuroscience Solutions, Inc. 207 West Gore Street, Suite 200, Orlando, FL 32806 2008- Present
Education	University of Central Florida, Orlando, Florida 1982-1985 University of Florida, Gainesville, Florida: College of Liberal Arts and Sciences; B.S. Psychology 1985-1987 College of Medicine; Doctor of Medicine 1987-1991
Professional Training	University of Virginia Health Sciences Center Dept. of Psychiatric Medicine: Resident 1991-1995 Chief Resident 1994-1995 Resident Selection Committee 1993-1995
License/ Accreditation	Licensure: Florida: ME-0067372 Virginia: 0116004239 Board Certification: American Board of Psychiatry and Neurology (#42570) Recertified 2006 American Society of Addiction Medicine Certified 2008 American Board of Addiction Medicine (#001228) 2009
Population Experience	<i>Adolescents:</i> Ten years clinical psychiatric experience with outpatient populations. Diagnoses include Mental Retardation, Learning Disorders, Pervasive Developmental Disorders, Tic Disorders, Delirium, Substance Abuse/ Dependence Disorders, Psychotic Disorders, Eating Disorders, Sleep Disorders, Impulse-Control Disorders, Mood Disorders, Anxiety Disorders and Adjustment Disorders. <i>Adults:</i> Eighteen years clinical psychiatric experience with inpatient and outpatient populations. Diagnoses include Mental Retardation, Learning Disorders, Tic Disorders, Delirium, Dementia, Amnesic Disorders, Substance Abuse/ Dependence Disorders, Psychotic Disorders, Mood Disorders, Bipolar Disorders, Anxiety Disorders, Somatoform Disorders, Factitious Disorders, Dissociative Disorders, Sexual and Gender Identity Disorders, Eating Disorders, and Impulse-Control Disorders. <i>Geriatrics:</i> Sixteen years clinical psychiatric experience with inpatient and outpatient populations. Diagnoses include Dementia, Delirium, Amnesic Disorders, Mood Disorders, Anxiety Disorders, Substance Abuse/ Dependence Disorders, Psychotic Disorders, Factitious Disorders, Sleep Disorders, Adjustment Disorders, and Personality Disorders.

Ratings and
Diagnostic
Experience

Psychiatric Evaluations, Medical Histories & Physicals, SCID, MINI, KSADS, MMSE, CGI-I, CGI-S, ADHD-RS, SCID-II, MADRS, HAM-D, CAARS, CAADID, C-SSRS, HAM-A, LSAS, ADAS, ADCS-ADL, AIMS, BARNES, BPRS, Calgary Depression Scale, CIBIC, ESRS, Family Impact Scale, PANSS, Quality of Life Assessment, SADS-C, Simpson-Angus, Y-BOCS, YMRS.

Clinical Trial
Experience

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Designed to Evaluate the Safety and Efficacy of XXXX in Children with Attention-Deficit/Hyperactivity (ADHD) Between 6-12 Years of Age

The Long-Term Safety and Tolerability of XXXX in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): An Open-Label Extension Study

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II Study of the Safety and Efficacy of 0.7 mg/kg/day and 1.4 mg/kg/day of XXXX in the Treatment of Children with Attention-Deficit/Hyperactivity (ADHD)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II Study of the Safety and Efficacy 40 mg QD and 80 mg QD of XXXX in Adults with Attention-Deficit/Hyperactivity (ADHD)

A Long-Term Safety and Tolerability of XXXX in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): An Open-Label Extension Study for Subjects Completing Study XXXX

A Phase III, Dose-Response Evaluation of the Efficacy and Safety of XXXX vs. Placebo in the Treatment of Children and Adolescents 6-17 Years of Age with Attention-Deficit/Hyperactivity Disorder (ADHD)

An Open-Label, Chronic Exposure Evaluation of the Safety of XXXX in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase II Study of 2 Oral Dose Groups of XXXX, with a Lorazepam Arm, in Subjects with Generalized Anxiety Disorder (GAD)

A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of XXXX Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women

A Phase II, 26-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX in Subjects with Alzheimer's Disease (AD) Receiving a Stable Dose of Donepezil

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX as Mono-Therapy in Subjects with Alzheimer's Disease

A Multicenter, Randomized, Open-Label, Controlled study to Evaluate the Safety, Tolerability, and Efficacy of XXXX When Added to XXXX in the Treatment of Fibromyalgia

A Randomized, Double-Blind, Placebo-and Active-Controlled Study of the Safety and Efficacy of XXXX in Patients with Diabetic Peripheral Neuropathic Pain

A Double-blind, Fixed-dose Study of XXXX in Adult Patients with Major Depressive Disorder (MDD)

A Long-Term, Open-Label Extension Study of XXXX in Adult Patients with Major Depressive Disorder (MDD)

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of XXXX in Subjects with Major Depressive Disorder (MDD)

A Three-Arm, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of XXXX for the Treatment of Adults with Stuttering

A Randomized, Double-Blind Comparison of XXXX and Placebo and Long Term Treatment with XXXX in Adult Patients with Major Depressive Disorder (MDD)

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of XXXX in Acute Treatment of Major Depressive Disorder (MDD) in Elderly Patients

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine Fumarate-Referenced, Fixed-Dose Study of XXXX in the Treatment of Depression in Patients with Bipolar I or II Disorder

A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of XXXX for Migraine Prophylaxis in Patients with Episodic Migraine

A Double-Blind, Placebo-Controlled Project of XXXX Adjunctive to Antidepressant Therapy (ADT) Among Outpatients with Major Depressive Disorder (MDD) Who Have Responded Inadequately to Prior ADT

An eight-week, Randomized, Fixed-Dosage, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety and Tolerability of XXXX 25 and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-Label Extension

An eight-week, Multicenter, Randomized, Double-Blind, Placebo-and Comparator-Controlled Study of the Efficacy, Safety and Tolerability of XXXX 25 or 50 mg Given Once Daily in the Treatment of Major Depressive Disorder (MDD) Followed By a 52-Week Open-Label Extension

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of XXXX in Patients with Recurrent Major Depressive Disorder (MDD)

A 52-Week, Open-label Extension Trial to Evaluate Safety and Efficacy of XXXX in Outpatients With Chronic Primary Insomnia

A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral XXXX as Add-On, Adjunctive Therapy with Lithium, Valproate or Lamotrigine in Bipolar I Depression

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Outpatient Trial of XXXX in Adults with Primary Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Ten-Week Study Evaluating the Efficacy and Safety of XXXX for the Treatment of Generalized Anxiety Disorder (GAD)

A 52-Week Open-Label Safety Study of XXXX in Subjects with GAD

A Phase III, Six-Month, Open-Label Safety Study of XXXX in Elderly Patients with Generalized Anxiety Disorder (GAD)

A One-Year Open-Label Study Assessing the Safety of XXXX in Patients with Major Depressive Disorder (MDD)

A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of XXXX in the Treatment of Bipolar I Depression

Efficacy and Safety of XXXX 5 mg/day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open-Treatment Phase Extension with XXXX for 40 Weeks Period

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Examining the Efficacy and Safety of XXXX in Subjects with Generalized Anxiety Disorder (GAD)

A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of XXXX in Adolescents aged 13-17 Years with Attention-Deficit/Hyperactivity Disorder

A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study, Designed to Evaluate the Safety and Efficacy of XXXX in Adolescents aged 13-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-Dose Titration, Safety and Efficacy Study of XXXX in Adolescents Aged 13-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase III, Open-Label, Extension, Multi-center, Safety and Efficacy Study of XXXX in Adolescents aged 13-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Dose Optimization Study Evaluating the Efficacy and Safety of XXXX in Combination with Psychostimulants in Children and Adolescents Aged 6-17 Years with a Diagnosis of Attention-Deficit/Hyperactivity Disorder

A Randomized, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of XXXX in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems

A Multicenter Randomized, Double-Blind, Placebo-Controlled, Phase II, Exploratory Study to Evaluate the Effect of XXXX on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder (GAD)

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Doses Study Comparing the Efficacy and Safety of 2 doses or XXXX in the Acute Treatment of Adults with Major Depressive Disorder (MDD)

A Long-Term, Open-Label, Flexible Dose, Extension Study Evaluating the Safety and Tolerability of XXXX in Subjects with Major Depressive Disorder (MDD)

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy of 3 Doses of XXXX in Acute Treatment of Adults with Generalized Anxiety Disorder (GAD)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Functional Outcome in Outpatients with Major Depressive Disorder (MDD) Treated with XXXX

Hospital
Appointments

Orlando Regional South Seminole Hospital, Behavioral Health Services:
Medical Director 03/04-04/05
Vice-Chair, Department of Psychiatry 2007-2009
Clinical Director & Founder, Program for Co-Occurring Illnesses (Dual-Diagnosis) 08/05-09/07

Lakeside Alternatives, Orlando, Florida:
Attending Psychiatrist, SRT-II (Short-Term Residential Treatment) 02/99-06/00
Attending Psychiatrist, Partial Hospitalization Program 08/98-01/99

Charter Behavioral Health System, Orlando, Florida; 1996-1997
Staff Psychiatrist 07/95-12/97
Medical Director 1996-1997
Service Director, Special Support Unit 1996-1997

On-Call Psychiatrist, Western State Hospital, Staunton, Virginia 1992-1995

Faculty	Lecture Series for second and third year medical students, University of Virginia 1992-1995
Appointments/ Teaching Activities	Coordinator, Psychopathology Series, University of Virginia College of Nursing 1995
	Preceptor, University of Florida Physician Assistant Program, 2000-2003; 2007-2008 Supervised 29 students, one month per student in the time frame
	Preceptor, Barry University Physician Assistant Program 2009
	University of Central Florida College of Medicine, Volunteer Faculty 2009-present
Professional Organizations	American Psychiatric Association
	Florida Psychiatric Association
	American Society of Addiction Medicine